Xcout Intel
Houdini Bio
Houdini Bio is a biotechnology company headquartered in London, United Kingdom, with operations in Cambridge. The firm focuses on genetic medicine to unlock its full therapeutic potential and advance curative treatments.
Subscribe to see Houdini Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Houdini Bio at a glance
Houdini Bio is a biotechnology company headquartered in United Kingdom, founded in 2025. Its most recent funding round, Pre-Seed, raised $1.9M in June 2026. Xcout tracks 4 named people at Houdini Bio, including Jonathan Cohen-Gold (CEO and co-founder).
Houdini Bio leadership
- Jonathan Cohen-GoldCEO and co-founder
- Lee DunhamCBO Co-Founder
- Harry Destecroix MBEInvestor Director
- Kerstin PapenfussInvestor Director
Houdini Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Pre-Seed | $1.9M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Houdini Bio competitors
A few of Houdini Bio's closest competitors — see the full list of competitors and alternatives →
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
ViaNautis Bio Ltd. is a groundbreaking nanomedicine company headquartered in Cambridge, UK, at the forefront of genetic therapies. The company leverages its proprietary polyNaut platform to develop novel products for delivering genetic medicines.
Hunterian Medicine LLC is a gene-editing company that develops CRISPR-based therapeutics to cure genetic diseases. The company utilizes a patented platform technology with a bidirectional promoter to enable efficient, on-target delivery of CRISPR via a single adeno-associated virus (AAV).
Tessera Therapeutics is a biotechnology company developing programmable genetic medicines using its Gene Writing technology, which is based on mobile genetic elements to insert, replace, or modify DNA in cells. It aims to develop treatments for genetic diseases and other serious conditions, serving patients who need durable genetic therapies.
Get Houdini Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Houdini Bio in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access